Atai Life Sciences announces first patient dosed in Phase 2 study of EMP-01

Atai Life Sciences (ATAI) announced that the first patient has been dosed in the exploratory Phase 2 study of EMP-01 for the treatment of social anxiety disorder. “We are pleased to have dosed the first patient in the exploratory Phase 2 study evaluating EMP-01 in adults with social anxiety disorder,” stated Kevin Craig, M.D., Chief Medical Officer of atai. “Social anxiety disorder affects millions and remains significantly underserved by current treatment options. We believe this Phase 2 study will provide critical insights into EMP-01’s potential to address this large and growing market with substantial unmet need.”